Investigational therapies for the treatment of atherosclerosis

Bibliography

• Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013;30:1762-5
   Google Scholar
• Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:998-1006
   PubMed Web of Science ®Google Scholar
• McGowan MP, Tardif JC, Ceska R, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One 2012;7:e49006
   PubMed Web of Science ®Google Scholar
• Santos RD, Duell PB, East C, et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J 2013. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Thomas GS, Cromwell WC, Ali S, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2013;62:2178
   PubMed Web of Science ®Google Scholar
• Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012;126:2283-92
   PubMed Web of Science ®Google Scholar
• Sjouke B, Balak DM, Beuers U, et al. Is mipomersen ready for clinical implementation? A transatlantic dilemma. Curr Opin Lipidol 2013;24:301-6
   PubMed Web of Science ®Google Scholar
• Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA 2003;100:928-33
   PubMed Web of Science ®Google Scholar
• Basak A, Chretien M, Seidah NG. A rapid fluorometric assay for the proteolytic activity of SKI-1/S1P based on the surface glycoprotein of the hemorrhagic fever Lassa virus. FEBS Lett 2002;514:333-9
   PubMed Web of Science ®Google Scholar
• Seidah NG, Hamelin J, Mamarbachi M, et al. cDNA structure, tissue distribution, and chromosomal localization of rat PC7, a novel mammalian proprotein convertase closest to yeast kexin-like proteinases. Proc Natl Acad Sci USA 1996;93:3388-93
   PubMed Web of Science ®Google Scholar
• Seidah NG, Chretien M, Day R. The family of subtilisin/kexin like pro-protein and pro-hormone convertases: divergent or shared functions. Biochimie 1994;76:197-209
   PubMed Web of Science ®Google Scholar
• Slack RS, El Bizri H, Wong J, et al. A critical temporal requirement for the retinoblastoma protein family during neuronal determination. J Cell Biol 1998;140:1497-509
   PubMed Web of Science ®Google Scholar
• Nuthall HN, Husain J, McLarren KW, Stifani S. Role for Hes1-induced phosphorylation in Groucho-mediated transcriptional repression. Mol Cell Biol 2002;22:389-99
   PubMed Web of Science ®Google Scholar
• Nguyen MA, Kosenko T, Lagace TA. Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts. J Lipid Res 2014;55:266-75
   PubMed Web of Science ®Google Scholar
• Desai NR, Giugliano RP, Zhou J, et al. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of NCEP-ATP III LDL-C goals among high risk patients: an analysis from the LAPLACE-TIMI 57 Trial. J Am Coll Cardiol 2014;63(5):430-3
   PubMed Web of Science ®Google Scholar
• Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013;128:2113-20
   PubMed Web of Science ®Google Scholar
• Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012;126:2408-17
   PubMed Web of Science ®Google Scholar
• Koren MJ, Giugliano RP, Raal FJ, et al. OSLER Investigators. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-label Study of Long-term Evaluation against LDL-C (OSLER) Randomized Trial. Circulation 2014;129:234-43
   PubMed Web of Science ®Google Scholar
• Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012;19;308:2497-506
   PubMed Web of Science ®Google Scholar
• Desai NR, Kohli P, Giugliano RP, et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation 2013;128:962-9
   PubMed Web of Science ®Google Scholar
• Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014;38360-8
   Google Scholar
• Lindholm MW, Elmén J, Fisker N, et al. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther 2012;20(2):376-81
   PubMed Web of Science ®Google Scholar
• HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34:1279-91
   PubMed Web of Science ®Google Scholar
• McGillicuddy FC, de la Llera Moya M, Hinkle CC, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009;3;119:1135-45
   PubMed Web of Science ®Google Scholar
• Tan Y, Liu TR, Hu SW, et al. Acute coronary syndrome remodels the protein cargo and functions of high-density lipoprotein subfractions. PLoS One 2014;9:e94264
   PubMed Web of Science ®Google Scholar
• Diffenderfer MR, Brousseau ME, Millar JS, et al. Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism. J Lipid Res 2012;53:1190-9
   PubMed Web of Science ®Google Scholar
• Bellanger NJulia ZVillard EF, et al. Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy. Atherosclerosis 2012;221:160-8
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tardif JC, Nicholls SJ, ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16
   PubMed Web of Science ®Google Scholar
• Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 2007;370:1907-14
   PubMed Web of Science ®Google Scholar
• Toft-Petersen AP, Tilsted HH, Aarøe J, et al. LDL particles–a predictor of coronary artery disease evaluated by invasive and CT-based techniques: a case-control study. Lipids Health Dis 2011;10:21
   PubMed Web of Science ®Google Scholar
• Han S, Levoci L, Fischer P, et al. Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein. Biochim Biophys Acta 2013;1831:825-33
   PubMed Web of Science ®Google Scholar
• Lüscher TF, Taddei S, Kaski JC, dal-VESSEL Investigators. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 2012;33:857-65
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Abt M, dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99
   PubMed Web of Science ®Google Scholar
• Ray KK, Ditmarsch M, Kallend D, on behalf of the dal-ACUTE Investigators. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. Eur Heart J 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011;306:2099-109
   PubMed Web of Science ®Google Scholar
• Siebel AL, Natoli AK, Yap FY, et al. Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion. Circ Res 2013;113:167-75
   PubMed Web of Science ®Google Scholar
• Creider JC, Hegele RA, Joy TR. Niacin: another look at an underutilized lipid-lowering medication. Nat Rev Endocrinol 2012;8:517-28
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292-3000
   PubMed Web of Science ®Google Scholar
• Sethi AA, Amar M, Shamburek RD, Remaley AT. Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. Curr Opin Investig Drugs 2007;8:201-12
   PubMed Web of Science ®Google Scholar
• Ditiatkovski M, D’Souza W, Kesani R, et al. An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice. PLoS One 2013;8:e68802
   PubMed Web of Science ®Google Scholar
• Waksman R, Torguson R, Kent KM, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010;55:2727-35
   PubMed Web of Science ®Google Scholar
• Bailey D, Jahagirdar R, Gordon A, et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol 2010;55:2580-9
   PubMed Web of Science ®Google Scholar
• McLure KG, Gesner EM, Tsujikawa L, et al. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS One 2013;8:e83190
   PubMed Web of Science ®Google Scholar
• Uehara Y, Ando S, Yahiro E, et al. FAMP, a novel apoA-I mimetic peptide, suppresses aortic plaque formation through promotion of biological HDL function in ApoE-deficient mice. J Am Heart Assoc 2013;2:e000048
   Web of Science ®Google Scholar
• Ramírez CM, Rotllan N, Vlassov AV, et al. Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. Circ Res 2013;112:1592-601
   PubMed Web of Science ®Google Scholar
• Rayner KJ, Suárez Y, Dávalos A, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010;328:1570-3
   PubMed Web of Science ®Google Scholar
• Dávalos A, Goedeke L, Smibert P, et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signalling. Proc Natl Acad Sci USA 2011;108:9232-7
   PubMed Web of Science ®Google Scholar
• Rotllan N, Ramírez CM, Aryal B, et al. Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr-/- mice–brief report. Arterioscler Thromb Vasc Biol 2013;33:1973-7
   PubMed Web of Science ®Google Scholar
• Robinson JG, Rogers WJ, Nedergaard BS, et al. Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled Trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol 2014;37(4):195-203
   PubMed Web of Science ®Google Scholar
• McFarlane MR, Liang G, Engelking LJ. Insig proteins mediate feedback inhibition of cholesterol synthesis in the intestine. J Biol Chem 2014;289:2148-56
   PubMed Web of Science ®Google Scholar
• Engelking LJ, McFarlane MR, Li CK, Liang G. Blockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytes. J Lipid Res 2012;53:1359-68
   PubMed Web of Science ®Google Scholar
• Li PS, Fu ZY, Zhang YY, et al. The clathrin adaptor Numb regulates intestinal cholesterol absorption through dynamic interaction with NPC1L1. Nat Med 2014;20:80-6
   PubMed Web of Science ®Google Scholar
• Hussain MM, Rava P, Walsh M, et al. Multiple functions of microsomal triglyceride transfer protein. Nutr Metab (Lond) 2012;9:14
   PubMed Web of Science ®Google Scholar
• Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007;356:148-56
   PubMed Web of Science ®Google Scholar
• Rizzo M, Wierzbicki AS. New lipid modulating drugs: the role of microsomal transport protein inhibitors. Curr Pharm Des 2011;17:943-9
   PubMed Web of Science ®Google Scholar
• Cuchel M, Meagher EA, du Toit Theron H, et al. Phase 3 HoFH Lomitapide Study investigators efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013;381:40-6
   PubMed Web of Science ®Google Scholar
• Aggarwal D, West KL, Zern TL, et al. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord 2005;5:30
   PubMedGoogle Scholar
• Hata T, Mera Y, Ishii Y, et al. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses food intake and gastric emptying with the elevation of plasma peptide YY and glucagon-like peptide-1 in a dietary fat-dependent manner. J Pharmacol Exp Ther 2011;336:850-6
   PubMed Web of Science ®Google Scholar
• Kim E, Campbell S, Schueller O, et al. A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile. J Pharmacol Exp Ther 2011;337:775-85
   PubMed Web of Science ®Google Scholar
• Soh J, Iqbal J, Queiroz J, et al. MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med 2013;19:892-900
   PubMed Web of Science ®Google Scholar
• Vickers KC, Moore KJ. Small RNA overcomes the challenges of therapeutic targeting of microsomal triglyceride transfer protein. Circ Res 2013;113:1189-91
   PubMed Web of Science ®Google Scholar
• Tomkin GH, Owens D. The chylomicron: relationship to atherosclerosis. Int J Vasc Med 2012;2012:784536
   PubMedGoogle Scholar
• Hu YW, Zhang P, Yang JY, et al. Nur77 Decreases Atherosclerosis Progression in apoE(-/-) Mice Fed a High-Fat/High-Cholesterol Diet. PLoS One 2014;9:e87313
   PubMed Web of Science ®Google Scholar